[ad_1]
Synopsis
India has been sending conflicting signals, resulting in ambiguity on its push for an international patent waiver on Covid-19 vaccines. But then, intellectual-property issues may not be the barrier to adequate availability of vaccines in India, and even if a waiver comes through, there may not be many takers for it.
Circa 2000. A devastating HIV-AIDS epidemic had engulfed continents. The previous year, 2.8 million people had succumbed to the virus, with sub-Saharan Africa bearing the brunt. Almost 19 million had perished from the time the outbreak started. The global count of newly infected HIV patients was a whopping 5.4 million.With the hope of reining in the virus fast ebbing, UK-based virologist Peter Piot, the executive director of a United Nations
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Why ?
-
Sharp Insight-rich, Indepth stories across 20+ sectors
-
Access the exclusive Economic Times stories, Editorial and Expert opinion
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link